Research programme: ubiquitin proteasome modulators - Nurix

Drug Profile

Research programme: ubiquitin proteasome modulators - Nurix

Alternative Names: UPS modulators

Latest Information Update: 30 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nurix
  • Developer Celgene Corporation; Nurix
  • Class Small molecules
  • Mechanism of Action Ubiquitin protein ligase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Inflammation

Most Recent Events

  • 17 Sep 2015 Nurix and Celgene collaborate for the discovery, development and commercialisation of small molecule therapeutics in oncology, inflammation and immunology
  • 16 Sep 2015 Early research in Inflammation in USA (unspecified route)
  • 29 May 2014 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top